We are thrilled to share that Biocytogen will attend the American Association for Cancer Research (AACR) Annual Meeting from April 19th - 22nd in San Diego, California. The premier event will feature a varied collection of methods workshops, special sessions, and major symposia. Come meet our team at booth #3225 to discover how Biocytogen’s established oncology and immuno-oncology models are driving the future of cancer research and treatments.
What is the AACR Annual Meeting 2026?
The AACR Annual Meeting is one of the largest oncology conferences in the world, uniting scientists, healthcare professionals, survivors, patients, and advocates to share the latest developments in cancer science. This year’s gathering will cover everything from translational studies and cancer biology, to survivorship and advocacy. Don’t miss out on this opportunity to network with the best minds in the cancer research community and form meaningful partnerships
Event Overview
Date: April 19th - 22nd, 2026
Venue: San Diego Convention Center, 111 Harbor Dr, San Diego, CA 92101
Event Schedule
For more information, please refer to the event schedule.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s shape the future of oncology research and treatment development together, we look forward to seeing you in San Diego!
